DK3362449T3 - Sibirilin-derivater til anvendelse til at forebygge og/eller behandle lidelser associeret med cellulær nekroptose - Google Patents
Sibirilin-derivater til anvendelse til at forebygge og/eller behandle lidelser associeret med cellulær nekroptose Download PDFInfo
- Publication number
- DK3362449T3 DK3362449T3 DK16781455.7T DK16781455T DK3362449T3 DK 3362449 T3 DK3362449 T3 DK 3362449T3 DK 16781455 T DK16781455 T DK 16781455T DK 3362449 T3 DK3362449 T3 DK 3362449T3
- Authority
- DK
- Denmark
- Prior art keywords
- prevention
- treatment
- disorders associated
- sibiriline
- derivatives
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N1/00—Preservation of bodies of humans or animals, or parts thereof
- A01N1/02—Preservation of living parts
- A01N1/0205—Chemical aspects
- A01N1/021—Preservation or perfusion media, liquids, solids or gases used in the preservation of cells, tissue, organs or bodily fluids
- A01N1/0226—Physiologically active agents, i.e. substances affecting physiological processes of cells and tissue to be preserved, e.g. anti-oxidants or nutrients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15306624 | 2015-10-13 | ||
| PCT/EP2016/074638 WO2017064217A1 (en) | 2015-10-13 | 2016-10-13 | Sibiriline derivatives for use for preventing and/or treating disorders associated with cellular necroptosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3362449T3 true DK3362449T3 (da) | 2021-07-19 |
Family
ID=54337712
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK16781455.7T DK3362449T3 (da) | 2015-10-13 | 2016-10-13 | Sibirilin-derivater til anvendelse til at forebygge og/eller behandle lidelser associeret med cellulær nekroptose |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US10426758B2 (da) |
| EP (1) | EP3362449B1 (da) |
| DK (1) | DK3362449T3 (da) |
| ES (1) | ES2885474T3 (da) |
| PL (1) | PL3362449T3 (da) |
| WO (1) | WO2017064217A1 (da) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3099037A1 (en) | 2018-05-03 | 2019-11-07 | Rigel Pharmaceuticals, Inc. | Rip1 inhibitory compounds and methods for making and using the same |
| PT3788045T (pt) | 2018-05-03 | 2023-06-26 | Rigel Pharmaceuticals Inc | Compostos inibidores de rip1 e métodos para fazer e usar os mesmos |
| CN111978311A (zh) * | 2019-05-21 | 2020-11-24 | 中国科学院上海有机化学研究所 | 一类细胞程序性坏死抑制剂及其制备方法和用途 |
| CN114761398A (zh) | 2019-09-06 | 2022-07-15 | 里格尔药品股份有限公司 | 杂环rip1激酶抑制剂 |
| TW202122397A (zh) | 2019-09-06 | 2021-06-16 | 美商雷傑製藥公司 | Ｒｉｐ１抑制性化合物及用於製備和使用其之方法 |
| JP7395730B2 (ja) | 2019-11-07 | 2023-12-11 | ライジェル ファーマシューティカルズ， インコーポレイテッド | ヘテロ環式ｒｉｐ１阻害化合物 |
| TWI824259B (zh) | 2020-07-01 | 2023-12-01 | 美商雷傑製藥公司 | Rip1k抑制劑 |
| CA3205853A1 (en) * | 2021-01-25 | 2022-07-28 | Stephane Bach | Use of indole, 6- and 7-azaindole derivatives as inhibitors of ferroptosis regulated cell death |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0115109D0 (en) * | 2001-06-21 | 2001-08-15 | Aventis Pharma Ltd | Chemical compounds |
| WO2005077344A2 (en) | 2003-08-29 | 2005-08-25 | The Brigham And Women's Hospital, Inc. | Hydantoin derivatives as inhibitors of cellular necrosis |
| CN101600714B (zh) * | 2006-11-10 | 2013-08-21 | 百时美施贵宝公司 | 吡咯并吡啶激酶抑制剂 |
| US20130059850A1 (en) * | 2010-05-06 | 2013-03-07 | Merck Sharp & Dohme Corp. | Aza-indole derivatives useful as modulators of faah |
| PL2935248T3 (pl) * | 2012-12-21 | 2018-07-31 | Plexxikon Inc | Związki i sposoby modulacji kinaz i wskazania dla nich |
| TW201613916A (en) * | 2014-06-03 | 2016-04-16 | Gilead Sciences Inc | TANK-binding kinase inhibitor compounds |
| PL3362450T3 (pl) * | 2015-10-13 | 2021-08-23 | Institut National De La Santé Et De La Recherche Médicale (Inserm) | N1 i n7-podstawione pochodne sybiriliny oraz ich zastosowania jako inhibitory nekroptozy komórkowej |
-
2016
- 2016-10-13 WO PCT/EP2016/074638 patent/WO2017064217A1/en active Application Filing
- 2016-10-13 PL PL16781455T patent/PL3362449T3/pl unknown
- 2016-10-13 ES ES16781455T patent/ES2885474T3/es active Active
- 2016-10-13 US US15/768,388 patent/US10426758B2/en active Active
- 2016-10-13 EP EP16781455.7A patent/EP3362449B1/en active Active
- 2016-10-13 DK DK16781455.7T patent/DK3362449T3/da active
Also Published As
| Publication number | Publication date |
|---|---|
| EP3362449B1 (en) | 2021-06-16 |
| PL3362449T3 (pl) | 2021-12-13 |
| EP3362449A1 (en) | 2018-08-22 |
| US20180325876A1 (en) | 2018-11-15 |
| US10426758B2 (en) | 2019-10-01 |
| ES2885474T3 (es) | 2021-12-13 |
| WO2017064217A1 (en) | 2017-04-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3149019T3 (da) | Cholan-derivater til anvendelse ved behandling og/eller forebyggelse af FXR- og TGR5/GPBAR1-formidlede sygdomme | |
| GB2548873B (en) | Use of Cannabidiol in the Treatment of SturgeWeber Syndrome | |
| DK3362449T3 (da) | Sibirilin-derivater til anvendelse til at forebygge og/eller behandle lidelser associeret med cellulær nekroptose | |
| DK3134125T3 (da) | Antistof-lægemiddel-konjugat og anvendelse deraf til behandling af cancer | |
| DK3395353T3 (da) | Plasminogen til anvendelse til behandling eller forebyggelse af diabetes-mellitus-nerveskade | |
| DK3481846T3 (da) | 11-substituerede 24-hydroxysteroler til anvendelse til behandling af nmda-relaterede tilstande | |
| DK3395359T3 (da) | Plasminogen til anvendelse til forebyggelse eller behandling af akut trombose og kronisk trombose | |
| DK3325509T3 (da) | Anti-tfr antistoffer og deres anvendelse i behandling af proliferative og inflammatoriske lidelser | |
| DK3102189T3 (da) | Sammensætning og fremgangsmåde til at fremme søvn | |
| DK3303339T3 (da) | Pde9-inhibitorer med imidazotriazinonskelet og imidazopyrazinonskelet til behandling af perifere sygdomme | |
| DK3882250T3 (da) | Tetrahydropyranyl-amino-pyrrolopyrimidinon til anvendelse i behandling af btk-medierede forstyrrelser | |
| DK3273995T3 (da) | Kombineret anvendelse af alginatoligomerer og cftr-modulatoren lumacaftor i behandlingen af tilstande associeret med cftr-dysfunktion | |
| DK3310190T3 (da) | Sammensætning til behandling af kød og anvendelse af denne | |
| HK1257169A1 (zh) | 用於治療cns和相關疾病的二氫吲哚-2-酮衍生物 | |
| DK3275453T3 (da) | Farmaceutisk sammensætning med silibinin og ve | |
| DK3325618T3 (da) | Hidtil ukendte trypsin-isoformer og anvendelse deraf | |
| DK3153511T3 (da) | 2-acylaminothiazolderivat til anvendelse i forebyggelsen eller behandlingen af blære- og urinvejssygdomme | |
| DK3187178T3 (da) | Sammensætning og lægemidler til reducering af lokaliseret fedt og kropsvægt og anvendelse heraf | |
| DK3328368T3 (da) | Forbindelser og farmaceutisk sammensætning associeret med ubiquitinering-proteasomsystem | |
| DK3283064T3 (da) | Derivater til anvendelse i behandling af muskelatrofi | |
| DK3529234T3 (da) | Forbindelser, fremgangsmåde til opnåelse af forbindelserne, farmaceutisk sammensætning, anvendelse af forbindelserne og fremgangsmåde til behandling af psykiatriske lidelser og/eller søvnforstyrrelser | |
| DK3157532T3 (da) | Fremgangsmåder til behandling og forebyggelse af sygdomme med vaskulær instabilitet | |
| DK3373922T3 (da) | Sammensætninger og fremgangsmåder til anvendelse i behandlingen af homocystinuri | |
| DK3197556T3 (da) | Sammensætning til forebyggelse og/eller behandling af allergisymptomer | |
| DK3439655T3 (da) | Ringfusionerede thiazolino 2-pyridoner, fremgangsmåder til fremstilling deraf og deres anvendelse i behandlingen og/eller forebyggelsen af tuberkulose |